In addition, the results of a large multicentre, open-label RCT investigating the “effects of long-term administration of human albumin on subjects with decompensated cirrhosis and ascites” (PRECIOSA study; NCT03451292), which enrolled more than 400 patients in Europe and the US with 1-year transplant-free survival as the primary endpoint, are expected at the end of 2024, and will provide a more complete assessment of efficacy than any retrospective study. This evidence concerns the gene ALB and Cirrhosis.